Chemotherapy and chemoembolization of patients with oncopathology as a risk factor for the development of myocardial dysfunction

Saule Kubekova, Natalya Zagorulya, Yelena Rib, Niyaz Malayev, Aruzhan Abdilda

2023

Full text Open access: Gold Metadata (CSL-JSON)
DOI 10.23950/jcmk/13122
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

Considering the aging of the population, the combination of cardiovascular diseases with oncopathology is gaining more relevance. Liver cancer occupies the 6th place in the structure of the incidence of neoplasms and the 3rd place in mortality from all oncological diseases. One of the main methods of treating patients with liver cancer is chemotherapy and chemoembolization, which significantly affect the myocardium, developing cardiotoxicity. Myocardial damage is reflected in the development of heart failure, which subsequently is the main cause of death in cancer patients.